[1]
|
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M. and Matrisian, L.M. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74, 2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
|
[2]
|
Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA Cancer Journal of Clinicians, 55, 74-108.
https://doi.org/10.3322/canjclin.55.2.74
|
[3]
|
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.
https://doi.org/10.1002/ijc.29210
|
[4]
|
Mittal, S. and El-Serag, H.B. (2013) Epidemiology of Hepatocellular Carcinoma: Consider the Population. Journal of Clinical Gastroenterology, 47, S2-S6.
https://doi.org/10.1097/MCG.0b013e3182872f29
|
[5]
|
Ozakyol, A. (2017) Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). Journal of Gastrointestinal Cancer, 48, 238-240.
https://doi.org/10.1007/s12029-017-9959-0
|
[6]
|
Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., et al. (2002) Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women. American Journal of Epidemiology, 155, 323-331. https://doi.org/10.1093/aje/155.4.323
|
[7]
|
Fattovich, G., Stroffolini, T., Zagni, I. and Donato, F. (2004) Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50.
https://doi.org/10.1053/j.gastro.2004.09.014
|
[8]
|
Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. and Ott, J.J. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013. Lancet, 386, 1546-1555.
https://doi.org/10.1016/S0140-6736(15)61412-X
|
[9]
|
Shi, J., Zhu, L., Liu, S. and Xie, W.F. (2005) A Meta-Analysis of Case-Control Studies on the Combined Effect of Hepatitis B and C Virus Infections in Causing Hepatocellular Carcinoma in China. British Journal of Cancer, 92, 607-612.
https://doi.org/10.1038/sj.bjc.6602333
|
[10]
|
Chan, H.L., Tse, C.H., Mo, F., Koh, J., Wong, V.W., Wong, G.L., et al. (2008) High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated with Increased Risk of Hepatocellular Carcinoma. Journal of Clinical Oncology, 26, 177-182.
https://doi.org/10.1200/JCO.2007.13.2043
|
[11]
|
Chu, Y.J., Yang, H.I., Wu, H.C., Liu, J., Wang, L.Y., Lu, S.N., et al. (2017) Aflatoxin B1 Exposure Increases the Risk of Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Virus Carriers. International Journal of Cancer, 141, 711-720.
https://doi.org/10.1002/ijc.30782
|
[12]
|
Chen, C.J., Yang, H.I. and Iloeje, U.H. (2009) Hepatitis B Virus DNA Levels and Outcomes in Chronic Hepatitis B. Hepatology, 49, S72-S84.
https://doi.org/10.1002/hep.22884
|
[13]
|
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. (2012) Sodium Taurocholate Cotransporting Polypeptide Is a Functional Receptor for Human Hepatitis B and D Virus. Elife, 1, e00049. https://doi.org/10.7554/eLife.00049
|
[14]
|
Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. (2015) Towards an HBV Cure: State-of-The-Art and Unresolved Questions—Report of the ANRS Workshop on HBV Cure. Gut, 64, 1314-1326.
https://doi.org/10.1136/gutjnl-2014-308943
|
[15]
|
Hsieh, A., Kim, H.S., Lim, S.O., Yu, D.Y. and Jung, G. (2011) Hepatitis B Viral X Protein Interacts with Tumor Suppressor Adenomatous Polyposis Coli to Activate Wnt/Beta-Catenin Signaling. Cancer Letters, 300, 162-172.
https://doi.org/10.1016/j.canlet.2010.09.018
|
[16]
|
Kuo TC, Chao CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem Pharmacol 2010 Oct 1;80(7):1093-1102.
|
[17]
|
Jung, S.Y. and Kim, Y.J. (2013) C-Terminal Region of HBx Is Crucial for Mitochondrial DNA Damage. Cancer Letters, 331, 76-83.
https://doi.org/10.1016/j.canlet.2012.12.004
|
[18]
|
Ching, R.H.H., Sze, K.M.F., Lau, E.Y.T., Chiu, Y.T., Lee, J.M.F., Ng, I.O.L., et al. (2017) C-Terminal Truncated Hepatitis B Virus X Protein Regulates Tumorigenicity, Self-Renewal and Drug Resistance via STAT3/Nanog Signaling Pathway. Oncotarget, 8, 23507-23516. https://doi.org/10.18632/oncotarget.15183
|
[19]
|
Zhu, R., Mok, M.T., Kang, W., Lau, S.S., Yip, W.K., Chen, Y., et al. (2015) Truncated HBx-Dependent Silencing of GAS2 Promotes Hepatocarcinogenesis through Deregulation of Cell Cycle, Senescence and p53-Mediated Apoptosis. The Journal of Pathology, 237, 38-49. https://doi.org/10.1002/path.4554
|
[20]
|
Yip, W.K., Cheng, A.S., Zhu, R., Lung, R.W., Tsang, D.P., Lau, S.S., et al. (2011) Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. PLoS ONE, 6, e22888.
https://doi.org/10.1371/journal.pone.0022888
|
[21]
|
Bozza, C., Cinausero, M., Iacono, D. and Puglisi, F. (2016) Hepatitis B and Cancer: A Practical Guide for the Oncologist. Critical Reviews in Oncology/Hematology, 98, 137-146.
|
[22]
|
Pattullo, V. (2016) Prevention of Hepatitis B Reactivation in the Setting of Immunosuppression. Clinical and Molecular Hepatology, 22, 219-237.
https://doi.org/10.3350/cmh.2016.0024
|
[23]
|
Lok, A.S., Ward, J.W., Perrillo, R.P., McMahon, B.J. and Liang, T.J. (2012) Reactivation of Hepatitis B during Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 156, 743-745.
https://doi.org/10.7326/0003-4819-156-10-201205150-00013
|
[24]
|
Bessone, F. and Dirchwolf, M. (2016) Management of Hepatitis B Reactivation in Immunosuppressed Patients: An Update on Current Recommendations. World Journal of Hepatology, 8, 385-394. https://doi.org/10.4254/wjh.v8.i8.385
|
[25]
|
Yasunaka, T., Ikeda, F., Wada, N., Morimoto, Y., Fujioka, S., Toshimori, J., et al. (2016) Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients. Acta Medica Okayama, 70, 1-12.
|
[26]
|
Cho, H., Ahn, H., Lee, D.H., Lee, J.H., Jung, Y.J., Chang, Y., et al. (2018) Entecavir and Tenofovir Reduce Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals. Journal of Viral Hepatitis.
https://doi.org/10.1111/jvh.12855
|
[27]
|
Wang, J.P., Kao, F.Y., Wu, C.Y., Hung, Y.P., Chao, Y., Chou, Y.J., et al. (2015) Nucleos(t)ide Analogues Associated with a Reduced Risk of Hepatocellular Carcinoma in Hepatitis B Patients: A Population-Based Cohort Study. Cancer, 121, 1446-1455.
https://doi.org/10.1002/cncr.29159
|
[28]
|
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A. and Cacciapuoti, C. (2016) Global Epidemiology of Hepatitis C Virus Infection: An Up-Date of the Distribution and Circulation of Hepatitis C Virus Genotypes. World Journal of Gastroenterology, 22, 7824-7840. https://doi.org/10.3748/wjg.v22.i34.7824
|
[29]
|
Rehermann, B. and Nascimbeni, M. (2005) Immunology of Hepatitis B Virus and Hepatitis C Virus Infection. Nature Reviews Immunology, 5, 215-229.
https://doi.org/10.1038/nri1573
|
[30]
|
El-Serag, H.B. (2011) Hepatocellular Carcinoma. The New England Journal of Medicine, 365, 1118-1127. https://doi.org/10.1056/NEJMra1001683
|
[31]
|
Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. (2015) Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease among Adults Awaiting Liver Transplantation in the United States. Gastroenterology, 148, 547-555. https://doi.org/10.1053/j.gastro.2014.11.039
|
[32]
|
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., et al. (1998) Binding of Hepatitis C Virus to CD81. Science, 282, 938-941.
https://doi.org/10.1126/science.282.5390.938
|
[33]
|
Sasaki, M., Yamauchi, K., Nakanishi, T., Kamogawa, Y. and Hayashi, N. (2003) In Vitro Binding of Hepatitis C Virus to CD81-Positive and -Negative Human Cell Lines. Journal of Gastroenterology and Hepatology, 18, 74-79.
https://doi.org/10.1046/j.1440-1746.2003.02925.x
|
[34]
|
Meredith, L.W., Wilson, G.K., Fletcher, N.F. and McKeating, J.A. (2012) Hepatitis C Virus Entry: Beyond Receptors. Reviews in Medical Virology, 22, 182-193.
https://doi.org/10.1002/rmv.723
|
[35]
|
Penin, F., Dubuisson, J., Rey, F.A., Moradpour, D. and Pawlotsky, J.M. (2004) Structural Biology of Hepatitis C Virus. Hepatology, 39, 5-19.
https://doi.org/10.1002/hep.20032
|
[36]
|
Lee, Y.A., Wallace, M.C. and Friedman, S.L. (2015) Pathobiology of Liver Fibrosis: A Translational Success Story. Gut, 64, 830-841.
https://doi.org/10.1136/gutjnl-2014-306842
|
[37]
|
Lemon, S.M. and McGivern, D.R. (2012) Is Hepatitis C Virus Carcinogenic? Gastroenterology, 142, 1274-1278. https://doi.org/10.1053/j.gastro.2012.01.045
|
[38]
|
Barazani, Y., Hiatt, J.R., Tong, M.J. and Busuttil, R.W. (2007) Chronic Viral Hepatitis and Hepatocellular Carcinoma. World Journal of Surgery, 31, 1243-1248.
https://doi.org/10.1007/s00268-007-9041-3
|
[39]
|
Hino, O., Kajino, K., Umeda, T. and Arakawa, Y. (2002) Understanding the Hypercarcinogenic State in Chronic Hepatitis: A Clue to the Prevention of Human Hepatocellular Carcinoma. Journal of Gastroenterology, 37, 883-887.
https://doi.org/10.1007/s005350200149
|
[40]
|
Henderson, N.C., Arnold, T.D., Katamura, Y., Giacomini, M.M., Rodriguez, J.D., McCarty, J.H., et al. (2013) Targeting of αv Integrin Identifies a Core Molecular Pathway That Regulates Fibrosis in Several Organs. Nature Medicine, 19, 1617-1624.
https://doi.org/10.1038/nm.3282
|
[41]
|
El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273.
https://doi.org/10.1053/j.gastro.2011.12.061
|
[42]
|
Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T. and Jennings, L.W. (2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology, 138, 513-521. https://doi.org/10.1053/j.gastro.2009.09.067
|
[43]
|
Calle, E.E. and Kaaks, R. (2004) Overweight, Obesity and Cancer: Epidemiological Evidence and Proposed Mechanisms. Nature Reviews Cancer, 4, 579-591.
https://doi.org/10.1038/nrc1408
|
[44]
|
Roche, B., Coilly, A., Duclos-Vallee, J.C. and Samuel, D. (2018) The Impact of Treatment of Hepatitis C with DAAs on the Occurrence of HCC. Liver International, 38, 139-145. https://doi.org/10.1111/liv.13659
|
[45]
|
Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y., et al. (2012) Chronic Hepatitis C Virus Infection Increases Mortality from Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. The Journal of Infectious Diseases, 206, 469-477. https://doi.org/10.1093/infdis/jis385
|
[46]
|
Ioannou, G.N., Green, P.K. and Berry, K. (2017) HCV Eradication Induced by Direct-Acting Antiviral Agents Reduces the Risk of Hepatocellular Carcinoma. Journal of Hepatology.
|
[47]
|
Colombo, M. and Boccaccio, V. (2018) Hepatitis C Eradication with DAA and Risk of Liver Cancer Recurrence: The Debate Unrests. Journal of Viral Hepatitis.
|
[48]
|
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. (2016) Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Journal of Hepatology, 65, 727-733. https://doi.org/10.1016/j.jhep.2016.06.015
|
[49]
|
Grandhe, S. and Frenette, C.T. (2017) Occurrence and Recurrence of Hepatocellular Carcinoma after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection. Gastroenterology & Hepatology, 13, 421-425.
|
[50]
|
Kozbial, K., Moser, S., Al-Zoairy, R., Schwarzer, R., Datz, C., Stauber, R., et al. (2017) Follow-Up of Sustained Virological Responders with Hepatitis C and Advanced Liver Disease after Interferon/Ribavirin-Free Treatment. Liver International.
|
[51]
|
Farazi, P.A. and DePinho, R.A. (2006) Hepatocellular Carcinoma Pathogenesis: From Genes to Environment. Nature Reviews Cancer, 6, 674-687.
https://doi.org/10.1038/nrc1934
|
[52]
|
Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., et al. (2012) A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2224-2260. https://doi.org/10.1016/S0140-6736(12)61766-8
|
[53]
|
Galicia-Moreno, M. and Gutierrez-Reyes, G. (2014) The Role of Oxidative Stress in the Development of Alcoholic Liver Disease. Revista de Gastroenterología de México, 79, 135-144. https://doi.org/10.1016/j.rgmx.2014.03.001
|
[54]
|
Ghouri, Y.A., Mian, I. and Rowe, J.H. (2017) Review of Hepatocellular Carcinoma: Epidemiology, Etiology, and Carcinogenesis. Journal of Carcinogenesis, 16, 1.
https://doi.org/10.4103/jcar.JCar_9_16
|
[55]
|
Hutchinson, S.J., Bird, S.M. and Goldberg, D.J. (2005) Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 3, 1150-1159.
|
[56]
|
Magnussen, A. and Parsi, M.A. (2013) Aflatoxins, Hepatocellular Carcinoma and Public Health. World Journal of Gastroenterology, 19, 1508-1512.
https://doi.org/10.3748/wjg.v19.i10.1508
|
[57]
|
Saad-Hussein, A., Taha, M.M., Beshir, S., Shahy, E.M., Shaheen, W. and Elhamshary, M. (2014) Carcinogenic Effects of Aflatoxin B1 among Wheat Handlers. International Journal of Occupational and Environmental Health, 20, 215-219.
https://doi.org/10.1179/2049396714Y.0000000069
|
[58]
|
Kew, M.C. (2013) Aflatoxins as a Cause of Hepatocellular Carcinoma. Journal of Gastrointestinal and Liver Diseases, 22, 305-310.
|
[59]
|
Qi, L.N., Bai, T., Chen, Z.S., Wu, F.X., Chen, Y.Y., De, X.B., et al. (2015) The p53 Mutation Spectrum in Hepatocellular Carcinoma from Guangxi, China: Role of Chronic Hepatitis B Virus Infection and Aflatoxin B1 Exposure. Liver International, 35, 999-1009. https://doi.org/10.1111/liv.12460
|
[60]
|
Hamid, A.S., Tesfamariam, I.G., Zhang, Y. and Zhang, Z.G. (2013) Aflatoxin B1-Induced Hepatocellular Carcinoma in Developing Countries: Geographical Distribution, Mechanism of Action and Prevention. Oncology Letters, 5, 1087-1092.
https://doi.org/10.3892/ol.2013.1169
|
[61]
|
Kucukcakan, B. and Hayrulai-Musliu, Z. (2015) Challenging Role of Dietary Aflatoxin B1 Exposure and Hepatitis B Infection on Risk of Hepatocellular Carcinoma. Open Access Macedonian Journal of Medical Sciences, 3, 363-369.
https://doi.org/10.3889/oamjms.2015.032
|
[62]
|
Liu, Y. and Wu, F. (2010) Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment. Environmental Health Perspectives, 118, 818-824.
|
[63]
|
Bellentani, S., Scaglioni, F., Marino, M. and Bedogni, G. (2010) Epidemiology of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 28, 155-161.
https://doi.org/10.1159/000282080
|
[64]
|
Said, A. and Ghufran, A. (2017) Epidemic of Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. World Journal of Clinical Oncology, 8, 429-436.
https://doi.org/10.5306/wjco.v8.i6.429
|
[65]
|
Benedict, M. and Zhang, X. (2017) Non-Alcoholic Fatty Liver Disease: An Expanded Review. World Journal of Hepatology, 9, 715-732.
https://doi.org/10.4254/wjh.v9.i16.715
|
[66]
|
Patel, V., Sanyal, A.J. and Sterling, R. (2016) Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clinical Liver Disease, 20, 277-292.
https://doi.org/10.1016/j.cld.2015.10.006
|
[67]
|
Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H. and Loomba, R. (2015) Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 13, 643-654. https://doi.org/10.1016/j.cgh.2014.04.014
|
[68]
|
Welzel, T.M., Graubard, B.I., Zeuzem, S., El-Serag, H.B., Davila, J.A. and McGlynn, K.A. (2011) Metabolic Syndrome Increases the Risk of Primary Liver Cancer in the United States: A Study in the SEER-Medicare Database. Hepatology, 54, 463-471.
https://doi.org/10.1002/hep.24397
|
[69]
|
Marengo, A., Rosso, C. and Bugianesi, E. (2016) Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine, 67, 103-117.
https://doi.org/10.1146/annurev-med-090514-013832
|
[70]
|
Chen, G., Ni, Y., Nagata, N., Xu, L. and Ota, T. (2016) Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 17, 1379. https://doi.org/10.3390/ijms17091379
|
[71]
|
Angulo, P. (2006) NAFLD, Obesity, and Bariatric Surgery. Gastroenterology, 130, 1848-1852. https://doi.org/10.1053/j.gastro.2006.03.041
|
[72]
|
Agosti, P., Sabba, C. and Mazzocca, A. (2018) Emerging Metabolic Risk Factors in Hepatocellular Carcinoma and Their Influence on the Liver Microenvironment. Biochimica et Biophysica Acta, 1864, 607-617.
https://doi.org/10.1016/j.bbadis.2017.11.026
|
[73]
|
Siddique, A. and Kowdley, K.V. (2011) Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma. Clinical Liver Disease, 15, 281-296. https://doi.org/10.1016/j.cld.2011.03.007
|
[74]
|
Hardy, T., Oakley, F., Anstee, Q.M. and Day, C.P. (2016) Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology, 11, 451-496. https://doi.org/10.1146/annurev-pathol-012615-044224
|
[75]
|
Ibrahim, S.H., Hirsova, P. and Gores, G.J. (2018) Non-Alcoholic Steatohepatitis Pathogenesis: Sublethal Hepatocyte Injury as a Driver of Liver Inflammation. Gut, 67, 963-972. https://doi.org/10.1136/gutjnl-2017-315691
|
[76]
|
Hirsova, P., Ibrahim, S.H., Gores, G.J. and Malhi, H. (2016) Lipotoxic Lethal and Sublethal Stress Signaling in Hepatocytes: Relevance to NASH Pathogenesis. The Journal of Lipid Research, 57, 1758-1770. https://doi.org/10.1194/jlr.R066357
|
[77]
|
Krenkel, O. and Tacke, F. (2017) Liver Macrophages in Tissue Homeostasis and Disease. Nature Reviews Immunology, 17, 306-321.
https://doi.org/10.1038/nri.2017.11
|
[78]
|
Heymann, F. and Tacke, F. (2016) Immunology in the Liver—From Homeostasis to Disease. Nature Reviews Gastroenterology & Hepatology, 13, 88-110.
https://doi.org/10.1038/nrgastro.2015.200
|
[79]
|
Koyama, Y. and Brenner, D.A. (2017) Liver Inflammation and Fibrosis. Journal of Clinical Investigation, 127, 55-64. https://doi.org/10.1172/JCI88881
|
[80]
|
Sera, T., Sumii, T., Fujita, R. and Kudo, S. (2018) Effect of Shear Stress on the Migration of Hepatic Stellate Cells. In Vitro Cellular & Developmental Biology—Animal, 54, 11-22. https://doi.org/10.1007/s11626-017-0202-x
|
[81]
|
Sanyal, A., Poklepovic, A., Moyneur, E. and Barghout, V. (2010) Population-Based Risk Factors and Resource Utilization for HCC: US Perspective. Current Medical Research and Opinion, 26, 2183-2191.
https://doi.org/10.1185/03007995.2010.506375
|
[82]
|
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., et al. (2011) Characteristics of Patients with Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 9, 428-433.
https://doi.org/10.1016/j.cgh.2011.01.023
|
[83]
|
Bianchini, F., Kaaks, R. and Vainio, H. (2002) Overweight, Obesity, and Cancer Risk. The Lancet Oncology, 3, 565-574.
https://doi.org/10.1016/S1470-2045(02)00849-5
|
[84]
|
Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., et al. (2010) Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell, 140, 197-208.
https://doi.org/10.1016/j.cell.2009.12.052
|
[85]
|
Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. The New England Journal of Medicine, 348, 1625-1638.
https://doi.org/10.1056/NEJMoa021423
|
[86]
|
Tournier, C. (2013) The 2 Faces of JNK Signaling in Cancer. Genes & Cancer, 4, 397-400. https://doi.org/10.1177/1947601913486349
|
[87]
|
Jiang, C.M., Pu, C.W., Hou, Y.H., Chen, Z., Alanazy, M. and Hebbard, L. (2014) Non Alcoholic Steatohepatitis a Precursor for Hepatocellular Carcinoma Development. World Journal of Gastroenterology, 20, 16464-16473.
https://doi.org/10.3748/wjg.v20.i44.16464
|
[88]
|
Schmidt-Arras, D. and Rose-John, S. (2016) IL-6 Pathway in the Liver: From Physiopathology to Therapy. Journal of Hepatology, 64, 1403-1415.
https://doi.org/10.1016/j.jhep.2016.02.004
|
[89]
|
Jiang, N., Sun, R. and Sun, Q. (2014) Leptin Signaling Molecular Actions and Drug Target in Hepatocellular Carcinoma. Drug Design, Development and Therapy, 8, 2295-2302.
|
[90]
|
Sharma, D., Wang, J., Fu, P.P., Sharma, S., Nagalingam, A., Mells, J., et al. (2010) Adiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis. Hepatology, 52, 1713-1722. https://doi.org/10.1002/hep.23892
|
[91]
|
Meex, R.C.R. and Watt, M.J. (2017) Hepatokines: Linking Nonalcoholic Fatty Liver Disease and Insulin Resistance. Nature Reviews Endocrinology, 13, 509-520.
https://doi.org/10.1038/nrendo.2017.56
|
[92]
|
Maximos, M., Bril, F., Portillo, S.P., Lomonaco, R., Orsak, B., Biernacki, D., et al. (2015) The Role of Liver Fat and Insulin Resistance as Determinants of Plasma Aminotransferase Elevation in Nonalcoholic Fatty Liver Disease. Hepatology, 61, 153-160. https://doi.org/10.1002/hep.27395
|
[93]
|
Cusi, K. (2016) Treatment of Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: Current Approaches and Future Directions. Diabetologia, 59, 1112-1120. https://doi.org/10.1007/s00125-016-3952-1
|
[94]
|
Starley, B.Q., Calcagno, C.J. and Harrison, S.A. (2010) Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection. Hepatology, 51, 1820-1832. https://doi.org/10.1002/hep.23594
|
[95]
|
Chun, Y.S., Huang, M., Rink, L. and Von Mehren, M. (2014) Expression Levels of Insulin-Like Growth Factors and Receptors in Hepatocellular Carcinoma: A Retrospective Study. World Journal of Surgical Oncology, 12, 231.
https://doi.org/10.1186/1477-7819-12-231
|
[96]
|
Mouzaki, M., Comelli, E.M., Arendt, B.M., Bonengel, J., Fung, S.K., Fischer, S.E., et al. (2013) Intestinal Microbiota in Patients with Nonalcoholic Fatty Liver Disease. Hepatology, 58, 120-127. https://doi.org/10.1002/hep.26319
|
[97]
|
Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., et al. (2013) Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection between Endogenous Alcohol and NASH. Hepatology, 57, 601-609.
https://doi.org/10.1002/hep.26093
|
[98]
|
Schloss, P.D. and Handelsman, J. (2004) Status of the Microbial Census. Microbiology and Molecular Biology Reviews, 68, 686-691.
https://doi.org/10.1128/MMBR.68.4.686-691.2004
|
[99]
|
Vyas, U. and Ranganathan, N. (2012) Probiotics, Prebiotics, and Synbiotics: Gut and Beyond. Gastroenterology Research and Practice, 2012, Article ID: 872716.
https://doi.org/10.1155/2012/872716
|
[100]
|
Koropatkin, N.M., Cameron, E.A. and Martens, E.C. (2012) How Glycan Metabolism Shapes the Human Gut Microbiota. Nature Reviews Microbiology, 10, 323-335.
https://doi.org/10.1038/nrmicro2746
|
[101]
|
Bull, M.J. and Plummer, N.T. (2014) Part 1: The Human Gut Microbiome in Health and Disease. Integrative Medicine (Encinitas), 13, 17-22.
|
[102]
|
Vanni, E. and Bugianesi, E. (2009) The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Another Pathway to Insulin Resistance? Hepatology, 49, 1790-1792.
https://doi.org/10.1002/hep.23036
|
[103]
|
Sanduzzi, Z.M., Rocco, A., Compare, D. and Nardone, G. (2017) The Gut Microbiota: A New Potential Driving Force in Liver Cirrhosis and Hepatocellular Carcinoma. United European Gastroenterology Journal, 5, 944-953.
https://doi.org/10.1177/2050640617705576
|
[104]
|
Compare, D., Coccoli, P., Rocco, A., Nardone, O.M., De Maria, S., Carteni, M., et al. (2012) Gut-Liver Axis: The Impact of Gut Microbiota on Non Alcoholic Fatty Liver Disease. Nutrition, Metabolism and Cardiovascular Diseases, 22, 471-476.
https://doi.org/10.1016/j.numecd.2012.02.007
|
[105]
|
Zhang, H.Y., Han, D.W., Su, A.R., Zhang, L.T., Zhao, Z.F., Ji, J.Q., et al. (2007) Intestinal Endotoxemia Plays a Central Role in Development of Hepatopulmonary Syndrome in a Cirrhotic Rat Model Induced by Multiple Pathogenic Factors. World Journal of Gastroenterology, 13, 6385-6395.
https://doi.org/10.3748/wjg.v13.i47.6385
|
[106]
|
Ruiz, A.G., Casafont, F., Crespo, J., Cayon, A., Mayorga, M., Estebanez, A., et al. (2007) Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis. Obesity Surgery, 17, 1374-1380.
https://doi.org/10.1007/s11695-007-9243-7
|
[107]
|
Borrelli, A., Bonelli, P., Tuccillo, F.M., Goldfine, I.D., Evans, J.L., Buonaguro, F.M., et al. (2018) Role of Gut Microbiota and Oxidative Stress in the Progression of Non-Alcoholic Fatty Liver Disease to Hepatocarcinoma: Current and Innovative Therapeutic Approaches. Redox Biology, 15, 467-479.
https://doi.org/10.1016/j.redox.2018.01.009
|
[108]
|
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., et al. (2017) Development of Hepatocellular Carcinoma in Japanese Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease: Association between PNPLA3 Genotype and Hepatocarcinogenesis/Fibrosis Progression. Hepatology Research, 47, 1083-1092.
https://doi.org/10.1111/hepr.12840
|
[109]
|
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nature Genetics, 40, 1461-1465. https://doi.org/10.1038/ng.257
|
[110]
|
Pirazzi, C., Valenti, L., Motta, B.M., Pingitore, P., Hedfalk, K., Mancina, R.M., et al. (2014) PNPLA3 Has Retinyl-Palmitate Lipase Activity in Human Hepatic Stellate Cells. Human Molecular Genetics, 23, 4077-4085.
https://doi.org/10.1093/hmg/ddu121
|
[111]
|
Huang, Y., Cohen, J.C. and Hobbs, H.H. (2011) Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease. The Journal of Biological Chemistry, 286, 37085-37093.
https://doi.org/10.1074/jbc.M111.290114
|
[112]
|
Pingitore, P., Pirazzi, C., Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. (2014) Recombinant PNPLA3 Protein Shows Triglyceride Hydrolase Activity and Its I148M Mutation Results in Loss of Function. Biochimica et Biophysica Acta, 1841, 574-580. https://doi.org/10.1016/j.bbalip.2013.12.006
|
[113]
|
Pirazzi, C., Adiels, M., Burza, M.A., Mancina, R.M., Levin, M., Stahlman, M., et al. (2012) Patatin-Like Phospholipase Domain-Containing 3 (PNPLA3) I148M (rs738409) Affects Hepatic VLDL Secretion in Humans and in Vitro. Journal of Hepatology, 57, 1276-1282. https://doi.org/10.1016/j.jhep.2012.07.030
|
[114]
|
Fields, A.L., Soprano, D.R. and Soprano, K.J. (2007) Retinoids in Biological Control and Cancer. Journal of Cellular Biochemistry, 102, 886-898.
https://doi.org/10.1002/jcb.21530
|
[115]
|
Sookoian, S., Castano, G.O. and Pirola, C.J. (2015) PNPLA3 I148M Variant Is Associated with Metabolic Stress-Response Phenotype in Patients with Nonalcoholic Fatty Liver Disease. Hepatology, 61, 1769.
https://doi.org/10.1002/hep.27390
|
[116]
|
Streba, L.A., Vere, C.C., Rogoveanu, I. and Streba, C.T. (2015) Nonalcoholic Fatty Liver Disease, Metabolic Risk Factors, and Hepatocellular Carcinoma: An Open Question. World Journal of Gastroenterology, 21, 4103-4110.
https://doi.org/10.3748/wjg.v21.i14.4103
|
[117]
|
Tsuchiya, N., Sawada, Y., Endo, I., Saito, K., Uemura, Y. and Nakatsura, T. (2015) Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 10573-10583. https://doi.org/10.3748/wjg.v21.i37.10573
|
[118]
|
Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022. https://doi.org/10.1002/hep.24199
|
[119]
|
European Association for the Study of The Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943.
https://doi.org/10.1016/j.jhep.2011.12.001
|
[120]
|
Chan, S.L., Mo, F.K., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., et al. (2009) New Utility of an Old Marker: Serial Alpha-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients with Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical Oncology, 27, 446-452.
https://doi.org/10.1200/JCO.2008.18.8151
|
[121]
|
de Lope, C.R., Tremosini, S., Forner, A., Reig, M. and Bruix, J. (2012) Management of HCC. Journal of Hepatology, 56, S75-S87.
https://doi.org/10.1016/S0168-8278(12)60009-9
|
[122]
|
Omata, M., Cheng, A.L., Kokudo, N., Kudo, M., Lee, J.M., Jia, J., et al. (2017) Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatology International, 11, 317-370.
https://doi.org/10.1007/s12072-017-9799-9
|
[123]
|
Carr, B.I., Guerra, V., Giannini, E.G., Farinati, F., Ciccarese, F., Rapaccini, G.L., et al. (2014) Low Alpha-Fetoprotein HCC and the Role of GGTP. The International Journal of Biological Markers, 29, e395-e402. https://doi.org/10.5301/jbm.5000092
|
[124]
|
Mita, Y., Aoyagi, Y., Yanagi, M., Suda, T., Suzuki, Y. and Asakura, H. (1998) The Usefulness of Determining Des-Gamma-Carboxy Prothrombin by Sensitive Enzyme Immunoassay in the Early Diagnosis of Patients with Hepatocellular Carcinoma. Cancer, 82, 1643-1648.
https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B
|
[125]
|
Okuda, H., Nakanishi, T., Takatsu, K., Saito, A., Hayashi, N., Watanabe, K., et al. (1999) Measurement of Serum Levels of Des-Gamma-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma by a Revised Enzyme Immunoassay Kit with Increased Sensitivity. Cancer, 85, 812-818.
https://doi.org/10.1002/(SICI)1097-0142(19990215)85:4<812::AID-CNCR8>3.0.CO;2-O
|
[126]
|
Higashi, T., Hasegawa, K., Kokudo, N., Makuuchi, M., Izumi, N., Ichida, T., et al. (2011) Demonstration of Quality of Care Measurement Using the Japanese Liver Cancer Registry. Hepatology Research, 41, 1208-1215.
https://doi.org/10.1111/j.1872-034X.2011.00880.x
|
[127]
|
Yu, R., Tan, Z., Xiang, X., Dan, Y. and Deng, G. (2017) Effectiveness of PIVKA-II in the Detection of Hepatocellular Carcinoma Based on Real-World Clinical Data. BMC Cancer, 17, 608. https://doi.org/10.1186/s12885-017-3609-6
|
[128]
|
Saitta, C., Raffa, G., Alibrandi, A., Brancatelli, S., Lombardo, D., Tripodi, G., et al. (2017) PIVKA-II Is a Useful Tool for Diagnostic Characterization of Ultrasound-Detected Liver Nodules in Cirrhotic Patients. Medicine (Baltimore), 96, e7266. https://doi.org/10.1097/MD.0000000000007266
|